Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Sutro Biopharma, Inc. (STRO) has a Wall Street consensus price target of $9.86, based on estimates from 19 covering analysts. With the stock currently trading at $20.47, this represents a potential downside of -51.8%. The company has a market capitalization of $1.74B.
Analyst price targets range from a low of $2.00 to a high of $15.00, representing a 132% spread in expectations. The median target of $10.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, STRO trades at a trailing P/E of -6.9x. Analysts expect EPS to grow -652.6% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how STRO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonSTRO's consensus price target is $9.86, -51.8% below the current price of $20.47. The 19 analysts tracking STRO see downside risk at present valuations.
STRO has a consensus rating of "Buy" based on 19 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $9.86 implies -51.8% downside from current levels.
STRO's current price is $20.47 with a consensus target of $9.86 (-51.8% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $15 for STRO, while the most conservative target is $2. The consensus of $9.86 represents the median expectation. These targets typically reflect 12-month expectations.
STRO is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STRO stock forecast based on 19 Wall Street analysts shows a consensus price target of $9.86, with estimates ranging from $2 (bear case) to $15 (bull case). The median consensus rating is "Buy".
Analysts are cautious on STRO, with 1 Sell ratings and a price target of $9.86 (-51.8% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STRO analyst price targets range from $2 to $15, a 132% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $9.86 consensus represents the middle ground.